Clinical Trial

A Study of CT0596 in Plasma Cell Leukemia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, exploratory dose-escalation and dosefinding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with PCL.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-16.
Status change: Not Yet Recruiting → Recruiting 2025-07-30
Trial Details
NCT Number NCT06988059
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: CARsgen Therapeutics Co., Ltd.
Conditions Plasma Cell Leukemia
Enrollment 27 participants
Start Date 2025-06-25
Primary Completion 2027-01-03 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-01